This landmark study is the first-ever side-by-side comparison of 171 antibodies against Ebola virus.
A one-two punch of powerful antibodies may be the best way to stop Ebola virus, reports an international team of scientists in the journal Cell. Their findings suggest new therapies should disable Ebola virus’s infection machinery and spark the patient’s immune system to call in reinforcements.
“This study presents results from an unprecedented international collaboration and demonstrates how 43 previously competing labs can together accelerate therapeutics and vaccine design,” says Erica Ollmann Saphire, PhD, professor at Scripps Research and director of the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC).
From 2013–2016, West Africa faced the deadliest Ebola outbreak the world has ever seen. By the time the outbreak was declared over, 11,325 people had died. The VIC is an international group of the world’s leading virologists, immunologists, systems biologists and structural biologists working to stop an outbreak on that scale from ever striking again.
The VIC researchers aim to understand which Ebola-fighting antibodies are best—and why. The hope is that the most effective antibodies can be combined in a therapeutic “cocktail.” Unlike an Ebola vaccine, these cocktails could be given to those already infected, which is important for stopping a disease that tends to emerge unexpectedly in remote locations.
Ollmann Saphire and her colleagues in the VIC have published more than 40 studies in just the last five years. This landmark study is the first-ever side-by-side comparison of 171 antibodies against Ebola virus and other related viruses, known as filoviruses. All antibodies in the panel were donated by different labs around the world, and many had not been previously characterized in such extensive detail.
“Through the VIC, we could test a larger pool of antibodies in parallel, which increased the potential to detect statistically significant relationships between antibody features and protection,” says Saphire. “We used this global pool of antibodies to evaluate, and streamline, the research pipeline itself.”
In addition to identifying links between antibody target locations and activity, VIC researchers tested this huge pool of antibodies to reveal which antibodies “neutralized” the virus, why neutralization assays so often disagree, and whether or not neutralization in test tubes adequately predicted how well these antibodies would protect live animals from Ebola virus infection. Unexpectedly, neutralization alone was not always associated with the protective ability of an antibody.
Notably, the scientists found nine antibodies that protected mice from infection without neutralizing the virus in test tubes. These antibodies likely fight infection by interacting with an infected person’s immune system, helping orchestrate a better immune response to the virus.
This “immune effector” activity is featured in the team’s companion study published simultaneously in Cell Host & Microbe. “The ability to evoke an immune response will likely represent a new avenue of study for therapeutic antibodies for Ebola virus infection,” says Sharon Schendel, project manager for the VIC and science writer in the Saphire lab.
From the large body of results, VIC member and Scripps Research faculty member Kristian Andersen, PhD, and his graduate student Karthik Gangavarapu developed a network describing how each antibody feature correlates to protection, which can serve as a guide to predict whether newly identified antibodies will have therapeutic value. Saphire says the next steps for the VIC are to further test promising antibody cocktails in non-human primates. The team will also pursue engineering of antibodies that carry signature features to better drive immune system response.
The Latest on: Ebola
via Google News
The Latest on: Ebola
- Supply chain delays affect planned stockpile of Ebola vaccineson January 19, 2021 at 5:02 pm
Supply chain delays must be addressed to speed up creation of a stockpile of vaccines against deadly Ebola disease, researchers say.
- International health organizations establish global Ebola vaccine stockpileon January 18, 2021 at 8:42 pm
The four leading international health and humanitarian organizations announced today the establishment of a global Ebola vaccine stockpile to ensure outbreak response.
- Ebola Vaccines Stockpiled Against Future Outbreakson January 12, 2021 at 1:52 am
The World Health Organization and partners say they are creating a global stockpile of Ebola vaccines to help stamp out future outbreaks.
- UNICEF, WHO, IFRC and MSF announce the establishment of a global Ebola vaccine stockpile [EN/AR/RU]on January 11, 2021 at 4:01 pm
Arabic News and Press Release on World about Disaster Management, Health and Epidemic; published on 12 Jan 2021 by IFRC, MSF and 3 other organizations ...
- WHO, Partners Announce Ebola Vaccine Stockpileon January 11, 2021 at 4:00 pm
Parts of the world ravaged by outbreaks of Ebola can now heave a small sigh of relief thanks to the stockpile of vaccine, the International Coordinating Group (ICG) announced Monday. The single-dose ...
- UNICEF, WHO, IFRC and MSF announce the establishment of a global Ebola vaccine stockpileon January 11, 2021 at 3:26 pm
The four leading international health and humanitarian organizations announced today the establishment of a global Ebola vaccine stockpile to ensure outbreak response. The effort to establish the ...
- Disease X: Doctor who discovered Ebola warns of deadly viruses yet to comeon January 4, 2021 at 11:26 pm
They are waiting for the results of a test for Ebola. The patient can only communicate with her relatives through a clear plastic observation window. Her identity is secret, to protect her from ...
- Disease X: The next pandemic? Doctor who discovered Ebola says 'new deadly viruses set to hit mankind'on January 4, 2021 at 5:42 am
Disease X: The next pandemic? Disease X, What is disease X, Ebola, Ebola virus, Democratic republic of Congo, Disease X WHO, DR Congo, disease x symptoms, disease x vaccine, disease x next ...
- Colonization Fueled Ebola: Dr. Paul Farmer on “Fevers, Feuds & Diamonds” & Lessons from West Africaon January 1, 2021 at 8:38 am
We continue our conversation with medical anthropologist Dr. Paul Farmer, whose new book, “Fevers, Feuds, and Diamonds,” tells the story of his efforts to fight Ebola in 2014 and how the ...
via Bing News